Parallax Volatility Advisers’s Madrigal Pharmaceuticals MDGL Stock Holding History

Parallax Volatility Advisers’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-9	Closed	-$1.57K	–	2369
2023 Q3	$1.31K	Buy	+9	New	+$1.69K	﹤0.01%	2201
2023 Q2	–	Sell	-3,084	Closed	-$835K	–	2711
2023 Q1	$747K	Buy	+3,084	New	+$840K	﹤0.01%	1613
2019 Q2	–	Sell	-149	Closed	-$19K	–	3290
2019 Q1	$19K	Sell	149 -2,020	-93%	-$251K	﹤0.01%	2505
2018 Q4	$244K	Buy	+2,169	New	+$336K	﹤0.01%	1699
2018 Q1	–	Sell	-630	Closed	-$58K	–	3449
2017 Q4	$58K	Buy	+630	New	+$36K	﹤0.01%	3141

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Parallax Volatility Advisers's MDGL Position: Q4 2023 in Review

Parallax Volatility Advisers sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2023, closing a stake of 9 shares — an estimated $1.57K sold.

Parallax Volatility Advisers first reported a position in MDGL in Q4 2017 and held it in 5 quarters. The position peaked at $747K in Q1 2023. 226 funds tracked by Wall St. Rank hold MDGL as of Q4 2023.

Parallax Volatility Advisers reported no remaining Madrigal Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 9 Madrigal Pharmaceuticals shares in Q4 2023, an estimated $1.57K.
Parallax Volatility Advisers first reported a position in Madrigal Pharmaceuticals in Q4 2017 and held it in 5 quarters.
Parallax Volatility Advisers's Madrigal Pharmaceuticals position peaked at $747K in Q1 2023.
226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2023.

Based on Parallax Volatility Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.